Habib Bank Limited

Habib Bank Limited (HBL), established in 1941, is Pakistan's first commercial bank and a leading financial institution in the country. Headquartered in Karachi, HBL operates over 1,640 branches and 2,264 ATMs globally, serving more than 40 million clients. In 2004, the Aga Khan Fund for Economic Development (AKFED) acquired a 51% stake in HBL, gaining management control. By April 2015, the Government of Pakistan divested its remaining 41.5% shareholding, making HBL Pakistan's largest private bank.

While HBL is primarily a commercial bank, it has diversified its services to include trade financing and facilitating international transactions. This diversification has positioned HBL as a key player in Pakistan's pharmaceutical import sector, particularly in sourcing finished pharmaceutical formulations from India. The bank's extensive network and financial expertise enable it to manage complex import operations, ensuring the availability of essential medicines in Pakistan.

HBL's distribution network is extensive, with over 1,640 branches and 2,264 ATMs across Pakistan and international locations. This widespread presence facilitates efficient logistics and distribution of imported pharmaceutical products. The bank's robust financial infrastructure supports seamless transactions and supply chain management, ensuring timely delivery of medicines to various stakeholders within Pakistan's healthcare system.

In Pakistan's pharmaceutical supply chain, HBL functions as a financial intermediary, facilitating the import of finished pharmaceutical formulations from India. By leveraging its banking and trade financing capabilities, HBL ensures the smooth procurement and distribution of essential medicines, thereby playing a crucial role in maintaining the country's pharmaceutical supply chain.

HBL's pharmaceutical imports from India are concentrated in a few key suppliers, with CIPLA LIMITED and BHARAT SERUMS AND VACCINES LIMITED accounting for a combined total of $1.77 million, representing approximately 83% of the total import value. This concentration indicates a strategic choice to source from established and reliable suppliers, ensuring consistent quality and supply. The stability of these relationships is evidenced by the frequency and volume of shipments, suggesting a strong and dependable supply chain.

HBL's supply chain resilience is bolstered by its partnerships with multiple Indian suppliers, including CIPLA LIMITED and BHARAT SERUMS AND VACCINES LIMITED. This diversification mitigates risks associated with single-source dependency. The bank's established relationships with these suppliers, evidenced by numerous shipments, indicate a stable and reliable supply chain. Additionally, HBL's extensive distribution network within Pakistan ensures that imported pharmaceutical products reach their destinations efficiently, further enhancing supply chain resilience.

HBL's sourcing pattern, characterized by partnerships with reputable Indian pharmaceutical suppliers, positions the bank as a reliable conduit for importing essential medicines into Pakistan. This strategy not only ensures a steady supply of high-quality pharmaceuticals but also strengthens HBL's competitive position in the market. For Indian exporters, establishing or enhancing relationships with HBL could provide a stable channel for distributing their products in Pakistan, leveraging HBL's established infrastructure and market presence.

The Drug Regulatory Authority of Pakistan (DRAP) is the primary regulatory body overseeing the import and distribution of pharmaceutical products in Pakistan. Established under the Drug Regulatory Authority of Pakistan Act, 2012, DRAP enforces the Drugs Act, 1976, and other relevant regulations to ensure the quality, safety, and efficacy of therapeutic goods. The Drugs (Labeling and Packaging) Rules, 1986, mandate that all imported packaged medicines display the name and prescription material in accordance with these regulations. (tipp.gov.pk)

To import pharmaceutical products into Pakistan, companies must obtain a Drug Import License (D.I.L.) from DRAP. The application process involves submitting necessary documents through DRAP's online portal, with a processing timeline of approximately five days. (dra.gov.pk) Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards recognized by DRAP, ensuring that products meet quality and safety requirements.

Imported pharmaceutical products must adhere to the Drugs (Labeling and Packaging) Rules, 1986, which require that all imported packaged medicines display the name and prescription material in accordance with these regulations. (tipp.gov.pk) This ensures that consumers and healthcare providers have access to accurate and essential information regarding the pharmaceutical products available in the market.

In March 2026, DRAP published a draft of the Therapeutic Goods (Import and Export) Rules, 2026, proposing updates to the regulatory framework governing the import and export of therapeutic goods in Pakistan. (dra.gov.pk) These proposed changes aim to streamline procedures and enhance the efficiency of the import and export processes for pharmaceutical products.

HBL's focus on importing finished pharmaceutical formulations, particularly in the advanced oncology category, aligns with the growing demand for cancer treatments in Pakistan. The substantial import value of Imatinib and Sorafenib indicates a strategic emphasis on providing essential oncology medications to meet the needs of patients. This product strategy reflects HBL's commitment to addressing critical healthcare requirements in the country.

HBL's sourcing strategy involves importing finished pharmaceutical formulations from established Indian suppliers, such as CIPLA LIMITED and BHARAT SERUMS AND VACCINES LIMITED. This approach ensures a consistent supply of high-quality products, particularly in the oncology therapeutic category. The bank's focus on finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-use products that can be directly distributed within Pakistan's healthcare system.

By importing a significant volume of oncology medications, HBL positions itself as a key supplier of essential cancer treatments in Pakistan. This market positioning serves a critical segment of the healthcare market, addressing the needs of patients requiring specialized and life-saving medications.

There is a realistic opportunity for new Indian suppliers to collaborate with HBL, especially in the oncology therapeutic category. The existing gaps in HBL's sourcing, such as the need for additional suppliers or alternative formulations, present avenues for new entrants to establish partnerships. Engaging with HBL could provide Indian exporters with a stable channel to distribute their products in Pakistan, leveraging HBL's established infrastructure and market presence.

Indian exporters seeking to supply pharmaceutical products to HBL and the Pakistan market must ensure that their products are registered with DRAP and comply with GMP standards recognized by the authority. Additionally, products must adhere to the labeling requirements set forth in the Drugs (Labeling and Packaging) Rules, 1986, ensuring that all imported packaged medicines display the name and prescription material in accordance with these regulations. (tipp.gov.pk)

Indian exporters interested in supplying pharmaceutical products to HBL should initiate contact by providing detailed product information, including registration status with DRAP and compliance with GMP standards. Participating in relevant tenders and trade fairs can also facilitate introductions. Understanding and adhering to Pakistan's regulatory requirements, including labeling and packaging standards, is crucial. Establishing a relationship with HBL may involve navigating the import licensing process and ensuring that all necessary certifications and approvals are in place.